Tirzepatide · GLP-1 and GIP · Differentiated

The Shot That Makes You Slim. And the Question No One Asks.

Tirzepatide has shown strong effects in registration trials. But before you decide on the shot, you should have heard the question that doesn't appear in any ad: why aren't you losing weight in the first place? A deep dive through studies, KPNI, anthroposophy, and what can block the path.

In my practice, this question comes up almost daily over the past few months. "What do you think of this shot? My colleague injects it. My friend too, and for her it apparently worked. Should I try it as well?" The short answer I give is rarely yes or no. It is: let's first answer two other questions. First, do you know why your body is not currently losing weight? Second, do you know what the shot triggers in your metabolism, the part that isn't in the ad? If after these two answers you still say, I want it, that's your decision. But please not before.

Please Read This First

Very important before you read on: if you are currently taking tirzepatide or a similar medication, please do not stop it on your own. In type 2 diabetes in particular, stopping abruptly can let blood sugar derail quickly. Everything written here is meant to help you have a better conversation with the doctor treating you, not to help you change something on your own.

And for context: this article is general health information and not advertising for a medicinal product. Tirzepatide is prescription-only. Whether it is an option for you is decided solely by the doctor treating you, on the basis of the official product information.

My Starting Point

I am not generally against this class of substances. In severe obesity with established complications, in type 2 diabetes with high cardiovascular risk, in people who have already tried a great deal, tirzepatide can be a sensible tool. That is part of the picture.

What concerns me: in German consultations, this class of substances is increasingly being prescribed to people who are five to fifteen kilograms overweight. Who do not eat "wrong." Whose bodies, for deep biological reasons, are not losing weight.

These people frequently have an untreated thyroid, chronic inflammation, heavy metal exposure, a history of mold, a derailed cortisol rhythm, or a hormonal imbalance. For them, the shot can miss the actual question.

This is the article I wished I'd had before the first patients put this topic on my desk. Not as an anti-pharma pamphlet. As a differentiation.

Part 1 · What Tirzepatide Does in the Body

The pharmacology, brief and honest. Then you understand what the shot does, and above all, what it doesn't do.

Tirzepatide is the active substance this article is about. I deliberately do not use trade names, the medication is prescription-only. Tirzepatide is a peptide injected subcutaneously once a week. It acts as a dual agonist at two hormone receptors at the same time: at the GLP-1 receptor and at the GIP receptor. Both receptors normally respond to hormones your own gut releases after eating. These hormones are called incretins. They lower blood sugar, increase insulin release, and signal satiety to the brain.

Tirzepatide mimics these hormones, but with a half-life of about five days. Your body therefore has a constant satiety signal for an entire week. You eat less because you feel less hunger. Gastric emptying slows. The reward system that normally responds to food with dopamine is dampened. You lose fat. Fast.

RCT, n=2,539Jastreboff et al., 2022, NEJM. The SURMOUNT-1 study

The pivotal phase-3 trial in 2,539 adults with obesity. Tirzepatide once weekly, 72 weeks long. The result: at the highest dose (15 mg), participants lost on average 20.9 percent of their body weight. Over 90 percent lost at least 5 percent. 57 percent lost at least 20 percent.

This is an effect size not previously known from obesity pharmacology. That belongs in the picture, and it belongs there as the strong side.

Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. doi.org/10.1056/NEJMoa2206038

Let that sink in. If the shot has such massive effects, where is the catch? The answer is not in the commercials. It is in the accompanying studies, in the phase-3 extensions, and in the pharmacology itself.

Part 2 · Three Risks That Belong in Every Consultation

Muscle loss. Rebound. Reward system. Three aspects that any serious patient education must include.

First: a relevant share of the lost weight is fat-free mass, not fat

This is the uncomfortable number that rarely appears prominently. With tirzepatide and similar agents, a considerable share of the weight lost can come from fat-free mass. In the review cited below it is around 10 percent of fat-free mass, roughly 6 kilograms. Fat-free mass is not just water. It is muscle, bone, connective tissue, organ mass, blood components. Exactly what you want to keep as you age.

~10%
loss of
fat-free mass
~6 kg
absolute loss
of fat-free mass
~10 yr
comparable to
a decade of aging
Narrative ReviewLocatelli et al., 2024, Diabetes Care. Incretin therapy and muscle mass

This review in Diabetes Care states it very clearly: GLP-1 and GIP agonists cause a loss of about 10 percent or roughly 6 kilograms of fat-free mass. Comparable to a decade of aging.

The authors stress that muscle mass in old age is central for function, metabolism, and mortality. Anyone who loses 6 kg of fat-free mass in one year between 50 and 60 has a different body afterwards. The recommendation: parallel, supervised resistance training of at least 10 weeks duration and high protein intake. Both are rare in real life.

Locatelli JC, Costa JG, Haynes A, et al. Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition? Diabetes Care. 2024;47(10):1718-1730. doi.org/10.2337/dci23-0100

ReviewStefanakis, Kokkorakis, Mantzoros, 2024, Metabolism

This Harvard review explicitly warns of the risk of sarcopenic obesity: a person who weighs less after tirzepatide but, relatively, has even more fat compared to muscle. This can permanently lower metabolic rate, increase fall risk, and accelerate frailty in old age.

The consequence: older people in particular, and those with already low muscle mass, are a high-risk group for exactly the outcome the therapy is supposed to protect them from.

Stefanakis K, Kokkorakis M, Mantzoros CS. The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health. Metabolism. 2024;161:156057. doi.org/10.1016/j.metabol.2024.156057

Second: after stopping, the weight comes back. Quickly.

This is the study that really every person considering the shot should know. It's called SURMOUNT-4. It was published in 2024 in JAMA. The question was simple: what happens when people who lost weight on tirzepatide stop the medication?

RCT, n=670Aronne et al., 2024, JAMA. SURMOUNT-4: what happens after stopping

783 adults with obesity received tirzepatide at maximum tolerated dose for 36 weeks. They lost an average of 20.9 percent of their body weight. 670 of them were then randomly divided into two groups: continued tirzepatide or placebo. 52 more weeks.

The result: the tirzepatide group continued to lose (-5.5 percent additional). The placebo group regained 14.0 percent. Statistically significant. Only 16.6 percent of the placebo group could maintain 80 percent of their original weight loss.

Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction: SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. doi.org/10.1001/jama.2023.24945

Case Series, n=9Kubota et al., 2023, Cureus. What happens 6 months after stopping

A small Japanese case series after SURPASS-J-mono: after stopping tirzepatide, HbA1c and body weight rose dose-dependently. Effects were measurable as early as two months. After six months a clear rebound, descriptive at such a small sample size, not statistically tested. Strongest at the highest prior dose.

Kubota M, Yamamoto K, Yoshiyama S. Effect on HbA1c and Body Weight After Discontinuation of Tirzepatide. Cureus. 2023;15(10):e46490. doi.org/10.7759/cureus.46490

What This Means in Practice

Tirzepatide is not a cure for obesity. It is a suppression. If you stop, the problem can come back, often with less favorable body composition, because fat-free mass was lost too. The consequence: either it becomes a long-term therapy, or the effect is very likely lost again after stopping. That is another reason never to decide on stopping alone, but always with the practice that prescribed it.

Lifelong therapy with a medication whose long-term safety over ten or twenty years no one knows yet, simply because it hasn't been on the market that long. That is an open point that needs to be named honestly.

Third: the reward system is dampened. Including what isn't food.

This is where it gets interesting. GLP-1 and GIP receptors don't just sit in the gut and the islets of the pancreas. They also sit in the hypothalamus, in the mesolimbic dopamine system, in the reward center. That is exactly the trick of why tirzepatide curbs cravings so effectively.

The open question: if I permanently modulate the reward system, am I only dampening the urge for food? Or am I also dampening other rewards? Sex? Music? Enthusiasm? Joy of life?

Reports from practice and first mechanistic studies suggest that some people on GLP-1 agonists describe a kind of emotional flatness, loss of drive, an anhedonia-like mood. That is not listed as a common side effect in the major approval studies, because it is rarely asked about. It is not causally proven. It is pharmacologically plausible, and I hear it in conversations. Systematic studies on this are still missing, so what I describe here is observation, not evidence.

Reframe Number 1

If you are currently depressed, in a phase of life with little joy, in a relationship slump, or in a burnout course, a shot that dampens the reward system can be exactly the wrong time capsule. You do lose weight. But you could simultaneously stop feeling what would pull you back into life.

And if you are doing really badly right now: if you have thoughts of taking your own life, do not wait for an appointment. In Germany, Telefonseelsorge is available around the clock at 0800 111 0 111, and in an emergency call 112.

Part 3 · Other Risks You Should Know

Pancreatitis, gastroparesis, thyroid C-cell warning. And what we simply don't know about long-term effects.

Cross-Sectional Analysis, n=10,328Aldhaleei et al., 2024. GI diagnoses under GLP-1 agonists

A cross-sectional analysis of the US All of Us cohort recorded, in over 10,000 adults on GLP-1 agonists (semaglutide, dulaglutide, liraglutide, exenatide, not tirzepatide), how frequently gastrointestinal diagnoses occurred in this group. Important for context: there was no comparison group, and those studied were on average over 60 and had multiple conditions.

Abdominal pain 57.6 percent. Constipation 30.4 percent. Diarrhea 32.7 percent. Nausea and vomiting 23.4 percent. Gastroparesis 5.1 percent. Pancreatitis 3.4 percent. Gastrointestinal bleeding 15.9 percent. These figures do not show how many people develop the complaints because of the medication, but how often such diagnoses were documented in this group at all. The authors themselves write that causality still needs to be clarified. They therefore cannot be transferred to tirzepatide.

Aldhaleei WA, Abegaz TM, Bhagavathula AS. Glucagon-like Peptide-1 Receptor Agonists Associated Gastrointestinal Adverse Events. Pharmaceuticals. 2024;17(2):199. doi.org/10.3390/ph17020199

Black Box Warning in the US

Tirzepatide carries a black box warning from the FDA in the US for medullary thyroid carcinoma and multiple endocrine neoplasia syndrome type 2. This warning comes from animal data in rats, in which GLP-1 agonists triggered C-cell tumors of the thyroid. In humans this has not yet been clearly demonstrated, but the signal is strong enough to contraindicate the substance in pre-existing or familial risk.

Practically: anyone with a family history of thyroid cancer should not receive tirzepatide without discussing it in detail.

Safety Points That Often Get Lost

Pregnancy and contraception. Two points women should definitely know: tirzepatide does not belong in pregnancy, and according to the product information it can impair the effectiveness of the oral contraceptive pill. At the start of therapy and after every dose increase, additional contraception is therefore recommended for some weeks. Raise this actively, it is often forgotten. The same caution applies while breastfeeding.

Hypoglycemia. If you also take insulin, sulfonylureas, or glinides, the risk of low blood sugar rises. Adjusting those medications belongs in medical hands, not in self-management.

Anesthesia and endoscopy. Gastric emptying can be delayed. Before any planned anesthesia, sedation, or gastroscopy, actively say that you are injecting an incretin medication; there are specific fasting recommendations for this.

Kidneys and liver. Persistent vomiting and diarrhea can worsen kidney function through fluid loss. With severe symptoms, see a doctor rather than simply continuing to inject. With acute, severe upper abdominal pain and vomiting, please seek medical help immediately, if in doubt via the emergency number.

Eating disorders. If you have or have had an eating disorder, an appetite-suppressing medication can reinforce an existing pattern. That belongs openly on the table before any decision.

Children and adolescents. This article speaks about adults. For children and adolescents, separate rules and a separate risk-benefit assessment apply.

Where you get it. Do not buy anything from online sellers without a prescription. Counterfeit and wrongly dosed products are in circulation, and with them you know neither what is inside nor who is liable.

ReviewReiss et al., 2025, Biomolecules. GLP-1 therapy and paths to discontinuation

This recent review summarizes the risks soberly: GI side effects common, pancreatitis and bowel obstruction rarer but real. Loss of muscle mass, premature facial skin aging ("Ozempic face"), and above all the high rate of weight regain after stopping. The authors advocate a strategy in which patients are first stabilized, then gently weaned, with simultaneous lifestyle implementation. In reality, this support structure is missing almost everywhere.

Reiss AB, Gulkarov S, Lau R, et al. Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss. Biomolecules. 2025;15(3):408. doi.org/10.3390/biom15030408

This is not "a bit of nausea." This is a pharmacologically deep, whole-body metabolic redirection. It deserves a level of patient education for which ten minutes are rarely enough.
Part 4 · The Most Important Question

You're not losing weight. But is it really about the food or the exercise? Or is it about something else?

Here is the question almost never asked before the shot lands on the table. The answer decides whether the shot makes any sense at all, or whether it is just an expensive suppression of an unsolved biological blockage.

Reframe Number 2

You are not too weak. You are not too undisciplined. You are not the reason your body is holding on to fat. Your body is holding on to fat because right now it has good reasons to hold on. These reasons are called hormones, inflammation, toxins, stress, sleep. If we don't look at them, every diet and every shot is a cosmetic solution against a biological wall.

In my practice I repeatedly see people who have not lost weight for years, even though they seem to be doing everything right. When we investigate thoroughly, we find one or several of the following factors in many of them. I keep no statistics on this, it is my clinical observation. These parameters are rarely part of the standard workup so far, in my view wrongly so.

Eight possible obstacles to weight loss that are rarely checked systematically
  1. Subclinical or untreated hypothyroidism (Hashimoto's). Hashimoto's thyroiditis can, once it leads into an underactive thyroid, lower basal metabolic rate and promote water retention. A link with insulin resistance via inflammatory messengers such as TNF-alpha is also discussed. That is mechanistically plausible, but not yet conclusively established in humans. Standard tests often only measure TSH. A real assessment requires TSH, fT3, fT4, TPO antibodies, and TG antibodies. More on this in the article Functional Hypothyroidism.

  2. Chronic low-grade inflammation ("adiposopathy"). Fat tissue is not just storage. It is hormonally active. In obesity it becomes inflamed. This inflammation drives insulin resistance, leptin resistance, and leptin hypothyrotropism. You eat, but your brain doesn't get the "full" signal. Helpful markers: hs-CRP, IL-6, ferritin, leptin, adiponectin.

  3. Chronic stress load and a derailed cortisol rhythm. High cortisol levels, especially in the evening, promote belly-fat storage via the HPA axis, generate insulin resistance, and stimulate reward eating. A salivary cortisol daily profile sees what a single morning blood draw never shows. More in the article Burnout.

  4. Heavy metal load as an obesogen. Mercury, cadmium, lead, aluminum. They can act xenoestrogenic and, in cell and animal models, disturb thyroid signaling pathways and mitochondrial enzymes and promote oxidative stress. Whether and from what level of exposure this relevantly affects weight and insulin sensitivity in humans is still open. On diagnostics: whole blood mineral analysis is established, while provoked urine testing is contested and viewed critically by toxicological societies. I use it only in selected cases and after detailed explanation. More in the article Heavy Metals.

  5. Mycotoxin load from mold. For mycotoxins, especially ochratoxin A and trichothecenes, cell and animal models show a burden on liver detoxification and an inhibition of mitochondrial energy production. In humans, the link with insulin sensitivity and weight is not yet established. Relevant above all in apartments with damp walls, in old buildings, after water damage. Diagnostics: a questionnaire on the living environment, plus the urinary mycotoxin profile, a self-pay test whose informative value is debated in the field. More in the article Mold.

  6. Estrogen dominance and low progesterone. A relative excess of estrogen compared with progesterone can go along with water retention, fat distribution at the belly and hips, and reduced insulin sensitivity. The term estrogen dominance is a working concept from functional medicine, not a recognized diagnosis. The evidence is thin, and what I describe here is a pattern I observe clinically. Diagnostics: hormones on day 19 to 22 of the cycle. More in the article Estrogen Dominance.

  7. Low testosterone in men. Men with low testosterone preferentially store belly fat, have less muscle mass, and less metabolic activity. Belly fat produces aromatase, which converts testosterone into estrogen. It is a self-reinforcing cycle. More in the article Testosterone Deficiency.

  8. Sleep deprivation and disturbed circadian rhythm. Less than seven hours of sleep reduces leptin, raises ghrelin, worsens insulin sensitivity, and increases cravings for carbohydrates. Anyone chronically sleeping too little has a metabolism that hoards fat. More in the article Sleep Disorders.

ReviewKhalil et al., 2023. Environmental toxins as adipogens

This review summarizes how persistent organic pollutants (POPs) and heavy metals disrupt metabolic function: POPs influence adipogenesis directly, heavy metals disturb glucose regulation via pancreatic beta cells and insulin signaling pathways. Endocrine disruptors in the prenatal phase raise fasting glucose later in life.

What this means: part of your present metabolic reality is not the result of what you ate yesterday. It is the result of what your mother breathed, what was in the water of your childhood, what was in the dental fillings of your grandparents.

Khalil WJ, Akeblersane M, Khan AS, Moin ASM, Butler AE. Environmental Pollution and the Risk of Developing Metabolic Disorders. Int J Mol Sci. 2023;24(10):8870. doi.org/10.3390/ijms24108870

ReviewSanyal & Raychaudhuri, 2016. Hypothyroidism and obesity

This Indian review makes it clear: between hypothyroidism and obesity there is a bidirectional relationship. Hypothyroidism lowers basal metabolic rate and leads to moderate weight gain. Conversely, obesity itself produces a secondary hyperthyrotropinemia via elevated leptin levels. Both reinforce each other.

The consequence: in obesity with elevated TSH, primary Hashimoto's must be distinguished from secondary obesity-related TSH elevation. Thyroid antibodies help with this.

Sanyal D, Raychaudhuri M. Hypothyroidism and obesity: An intriguing link. Indian J Endocrinol Metab. 2016;20(4):554-557. doi.org/10.4103/2230-8210.183454

ReviewAdam & Epel, 2007. Stress, eating, reward

This widely cited review on the stress-eating hypothesis shows: chronic stress activates the HPA axis, raises cortisol, promotes visceral belly fat, and shifts the reward system toward calorie-rich, highly palatable food. The authors describe "reward-based stress eating" as a model in which cortisol, insulin, leptin, and NPY interact to raise the reward value of food.

The consequence: under chronic stress, your brain is working against you. Tirzepatide can mask this. Tirzepatide cannot solve the stress.

Adam TC, Epel ES. Stress, eating and the reward system. Physiol Behav. 2007;91(4):449-458. doi.org/10.1016/j.physbeh.2007.04.011

Anyone who loses weight without knowing why they hadn't lost weight has not lost weight. They have shifted a number.
Part 5 · KPNI · The Four Lenses

Obesity is not an energy problem. It is a communication problem between the nervous system, the immune system, the hormone system, and metabolism.

In clinical psycho-neuro-immunology we don't only look at calories. We look at the interplay of four systems. Obesity arises when these four systems no longer talk to each other but only fight for their own stability.

Nervous System

The vagus nerve regulates satiety, appetite, digestion, and inflammation via the gut-brain axis. Under chronic stress, low vagal activity, and disturbed HRV, you lose the normal sensation of fullness. Tirzepatide replaces this signal pharmacologically. It does not change vagal function itself.

Immune System

Fat tissue is an immunological organ. In obesity it is chronically inflamed. This inflammation blocks leptin and insulin signaling pathways in the hypothalamus. You eat, but your brain doesn't register it. As long as the inflammation runs, sustained weight loss is physiologically harder.

Metabolism

Insulin resistance is not the end stage. It is the beginning. It blocks fat burning and forces your body to store fat instead of mobilizing it. Anyone wanting to lose weight must first restore insulin sensitivity. Only then does the fat flow.

Hormone System

Thyroid, sex hormones, cortisol, leptin, ghrelin, GLP-1, GIP, insulin, adiponectin. They all direct whether your body runs in build-up or break-down mode. If just one of these hormones is out of balance, it can block all the others. Tirzepatide intervenes there at one point. The system is more than one point.

These four lenses explain why a shot that intervenes at only one point is often not enough. And why it sometimes pushes the system further out of balance.

Part 6 · The Anthroposophic View

How would Rudolf Steiner classify tirzepatide? A complementary perspective.

Anthroposophic medicine has a different language than conventional medicine. It complements conventional medicine, it does not replace it. If you want to read more about the scientific foundations of anthroposophic medicine, you can find that in my article Whoever Heals, Is Right.

Steiner describes the human being as a being with four members. This is not esoteric muddle. It is a functional description that speaks a different language than natural-science medicine and can therefore ask questions that are methodologically not provided for there. It replaces nothing, it complements. It can, for example, describe what happens to consciousness, joy of life, and inner warmth when a therapy intervenes in self-regulation.

I
Physical
Matter, minerals, what can be weighed and measured.
II
Etheric
Life processes, growth, metabolism, regeneration.
III
Astral
Sensation, desire, drive, lust, hunger and satiety.
IV
I
Self-aware center, inner warmth, self-regulation.
An Anthroposophic Perspective on Tirzepatide

If metabolism is the work of the I, what happens when we move it to the outside?

In Steiner's description, the metabolism of the human being is not a passive chemical process. It is an activity. One in which the I of the human being penetrates the world it has taken in, transforms it, makes it its own. The human eats the world and from it makes themselves. This transformation does not happen in the refrigerator of the body. It happens as an active, warm, individual act.

If I now give a medication that produces satiety signals from the outside, that dampens the reward system, that slows the stomach, then the medication takes over tasks that, in Steiner's model, belong to the activity of the I. The I no longer experiences itself as regulator. It experiences itself as regulated. Long enough taken, this could, the anthroposophic tradition suspects, lead to the I losing its own activity in relation to metabolism. To the inner warmth that goes along with enjoyment, with desire, with active living, being dampened.

This fits with what patients on GLP-1 agonists sometimes describe: a feeling of "life on low burn." A loss of enjoyment, not just of hunger. A loss of warmth, in both the literal and figurative sense.

This view is not a scientific study. It is a complement. It helps perceive symptoms that aren't queried in the double-blind trial. It makes us alert to a question beyond weight: is this person actually still living their life, or a dampened version of it?

Reframe Number 3

Most likely it lies in between. Tirzepatide is not "evil." But it is also not harmless. It is a technological intervention into a central self-regulation. Anyone who has understood that will dose, accompany, and use the shot differently than someone who treats it as a slimming drug.

Part 7 · How I Proceed

My diagnostic path, before we even talk about tirzepatide.

When someone comes to me with the wish for a weight-loss shot, it is not first about a prescription with me. It is about understanding. Before I even come close to a prescription, I ask these questions and run this diagnostic.

What should be checked before a tirzepatide decision
  • Thyroid full panel: TSH, fT3, fT4, TPO-Ab, TG-Ab, reverse T3
  • Insulin and glucose: fasting glucose, fasting insulin, HOMA-IR, HbA1c
  • Lipids full panel: triglycerides, HDL, LDL including subclasses, Apo-B, Lp(a)
  • Inflammation markers: hs-CRP, IL-6, ferritin, homocysteine
  • Hormones: salivary cortisol daily profile, sex hormones cycle-dependent (in women day 19 to 22), free and total testosterone (in men), DHEA-S, SHBG
  • Micronutrients: vitamin D, B12, folate, magnesium, zinc, selenium, iron status
  • Toxins where clinically suspected: heavy metals (whole blood, where appropriate provoked), mycotoxins in urine
  • Lifestyle history: sleep architecture, stress load, exercise, sun, social bonds
  • Biographical history: when did the weight plateau begin, what happened at the same time, is there a traumatic event as trigger

That sounds elaborate. It is elaborate. But it is the only way to see a human being instead of seeing a BMI number. And it is the prerequisite for tirzepatide, if it is prescribed at all, to be embedded in an accompanied path and not in a vacuum.

Three levers that in my view come first, before we even talk about shots

First, restore insulin sensitivity. Fast carbohydrates out, especially after 6 PM. Three meals per day, no snacks. Movement built into the day, ideally before or directly after meals. Sleep from 10 PM to 6 AM in the dark season. These four levers can influence insulin sensitivity favorably. In practice I often see changes after some weeks to months; it cannot be guaranteed, and how strong the effect turns out is highly individual.

An important restriction: if you take insulin, sulfonylureas, or glinides, dropping snacks can trigger hypoglycemia. In that case please change your meal structure only together with the doctor who manages your medication.

Second, strength training three times per week, at least 30 minutes. Working muscle can take up glucose even without insulin; the contraction itself opens the transport route. That is one reason why strength training influences blood sugar differently than diet alone. More muscle can raise metabolic rate, improve glucose regulation, and lower fall risk. In observational studies, higher muscle strength also goes along with lower mortality. Whether that is causal cannot be derived from this. If you have a cardiovascular condition or an orthopedic problem, get medical clearance first and have the exercises supervised.

Third, address possible blockages. If diagnostics give an indication: get the thyroid properly managed, have mold exposure in the home remediated, support the hormonal balance and the cortisol rhythm. On chelation of heavy metals: this is a procedure with its own risks, among them for the kidneys and the mineral balance, and the evidence on weight effects is thin. If at all, it belongs in a careful medical risk-benefit assessment and not on a weight-loss list. Each of these measures can set a plateau in motion; certain it is not.

Who this does not apply to: if there is severe obesity with secondary conditions, type 2 diabetes with high cardiovascular risk, or a finding that needs acute treatment, then we do not search for a year first. Then guideline-based drug therapy starts right away, and the search for causes runs alongside it. The path described here is for the group carrying five to fifteen kilograms, where there is time.

If after all this it becomes clear in six to twelve months that pharmacological support makes sense, tirzepatide can be a tool. Not the first. Sometimes not the right one. Sometimes very much the appropriate one. But then with eyes that are open, with strength training as mandatory companion, with high-quality protein intake, with a clear weaning strategy, and with knowledge of what you are doing.

True Freedom

You don't have to choose between "shot or stay as you are." That choice was sold to you wrong.

The advertising narrative goes: you suffer from your weight, other methods don't work, here is the modern solution. What gets lost in this narrative: many people who don't lose weight never had the opportunity for a genuinely broad search for causes. That is rarely down to the will of those treating them. It is down to time pressure, budgets, and the fact that these parameters are not in the standard benefit catalogue.

You can reject both. The fatalistic version "well, then I'll just live with overweight." And the quick fix "then I'll take the shot and everything will be fine." You can choose instead the path that is more work and asks more questions. The path that asks: why is my body holding on to fat? What is it telling me with this? And what of it can be changed?

Energy, clarity, joy of life, warmth. That is what it is about in the end. Not a BMI number on a slip of paper. Not a quick change in the mirror that disappears with rebound after stopping.

Concrete Levers

Three things you can do this week before even thinking about the shot.

First, raise the topic of a broader workup. A TSH value alone cannot fully picture a thyroid situation. What can make sense: the complete thyroid panel, HOMA-IR, a cortisol profile, the sex hormones. Part of this is covered by health insurance, part is not, and for some of these parameters the benefit is contested in the field. At an appointment I will lay out openly what is well established and what is not, and what it costs, before we arrange anything.

Second, focus first on insulin resistance and sleep. Fast carbohydrates out, three meals per day, no snacking, sleep from 10 PM to 6 AM. Strength training three times per week. These levers can change your metabolic profile favorably; how fast and how strongly differs from person to person. They make sense before any shot and before any diet. If you take blood-sugar-lowering medication, please only in medical coordination.

Third, ask yourself honestly why your body is holding on to fat. What was happening in your life when the plateau began? Stress, grief, sleeplessness, a pregnancy, a burnout, mold in your apartment, a flare-up of a chronic condition? This biographical question is medically often more important than any laboratory number.

This article is general health information and not advertising for a medicinal product. Tirzepatide is prescription-only. Whether it is an option for you is decided solely by the doctor treating you, on the basis of the official product information. If you want to understand why your body is currently not losing weight, you can book an appointment for a holistic search for causes below this article. Together we then go through all the axes.

Sources

Tirzepatide: efficacy and study landscape

Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. doi.org/10.1056/NEJMoa2206038 [SURMOUNT-1, RCT, n=2,539]

Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. doi.org/10.1001/jama.2023.24945 [SURMOUNT-4, RCT, n=670, discontinuation study]

Kubota M, Yamamoto K, Yoshiyama S. Effect on HbA1c and Body Weight After Discontinuation of Tirzepatide. Cureus. 2023;15(10):e46490. doi.org/10.7759/cureus.46490 [Case series, rebound after stopping]

Tirzepatide: risks and side effects

Locatelli JC, Costa JG, Haynes A, et al. Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition? Diabetes Care. 2024;47(10):1718-1730. doi.org/10.2337/dci23-0100 [Review, muscle mass loss]

Stefanakis K, Kokkorakis M, Mantzoros CS. The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health. Metabolism. 2024;161:156057. doi.org/10.1016/j.metabol.2024.156057 [Review, sarcopenia risk]

Aldhaleei WA, Abegaz TM, Bhagavathula AS. Glucagon-like Peptide-1 Receptor Agonists Associated Gastrointestinal Adverse Events. Pharmaceuticals (Basel). 2024;17(2):199. doi.org/10.3390/ph17020199 [Cross-sectional analysis without control group, n=10,328]

Reiss AB, Gulkarov S, Lau R, et al. Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss. Biomolecules. 2025;15(3):408. doi.org/10.3390/biom15030408 [Review, discontinuation strategies]

What prevents weight loss: hormonal, immunological, toxicological

Sanyal D, Raychaudhuri M. Hypothyroidism and obesity: An intriguing link. Indian J Endocrinol Metab. 2016;20(4):554-557. doi.org/10.4103/2230-8210.183454 [Review]

Artasensi A, Mazzolari A, Pedretti A, Vistoli G, Fumagalli L. Obesity and Type 2 Diabetes: Adiposopathy as a Triggering Factor. Molecules. 2023;28(7):3094. doi.org/10.3390/molecules28073094 [Review, obesity and inflammation]

Khalil WJ, Akeblersane M, Khan AS, Moin ASM, Butler AE. Environmental Pollution and the Risk of Developing Metabolic Disorders: Obesity and Diabetes. Int J Mol Sci. 2023;24(10):8870. doi.org/10.3390/ijms24108870 [Review, obesogens and heavy metals]

Adam TC, Epel ES. Stress, eating and the reward system. Physiol Behav. 2007;91(4):449-458. doi.org/10.1016/j.physbeh.2007.04.011 [Mechanism review, cortisol and visceral fat]

Note on methodology. This article follows the differentiated model of KPNI and lifestyle medicine. Statements about effect, risk, and outcomes are to be understood as references to mechanisms and possible relationships, not as health promises. The anthroposophic view is marked as a complementary perspective, not as scientific proof. It cannot be validated by double-blind trials because it does not speak in their language. The pharmacological risks, by contrast, are evidence-based. Treatment decisions, especially regarding tirzepatide, belong in the hands of a qualified medical professional who knows your values, your life situation, and your biographical history. Where an area is based on few, sometimes contradictory studies, I point this out in the text. The data on long-term effects over ten or twenty years is not yet available for tirzepatide because the substance has not been used over those time periods. Making this uncertainty transparent is part of serious science communication.

Have questions or want to book an appointment?

We'd be happy to advise you personally at our practice.

Book appointment